Bijoy Hans Ltd: BSE Approves Preferential Share Trading

Bijoy Hans Limited has received trading approval from the Bombay Stock Exchange (BSE) for 4,05,21,836 equity shares, issued at ₹12.50 each. These shares will be tradable starting April 23, 2026. This capital infusion is expected to significantly increase the company's equity base and enhance its stock's market liquidity.

Trading Approval Granted by BSE

The BSE has officially approved the trading of 4,05,21,836 equity shares issued by Bijoy Hans Limited. The shares were allotted to both promoters and non-promoters at a price of ₹12.50 each, comprising a face value of ₹10 and a premium of ₹2.50. Trading for these new shares is set to commence on April 23, 2026. This development will expand the company's equity capital and is anticipated to improve the liquidity of its stock.

Why This Matters for Investors

This BSE approval is a key step in Bijoy Hans's capital-raising strategy, injecting fresh equity into its operations. The listing of these shares on the exchange is vital for their future market engagement. For shareholders, this represents a shift in the company's capital structure. The increase in the total number of shares outstanding may lead to dilution, but it could also attract strategic investors or provide funds for business expansion.

Company Background

Established in 1985, Bijoy Hans Limited operates in the trading of bulk drugs, pharmaceuticals, and cosmetics, alongside investment activities. The company has previously engaged in capital-raising initiatives, with several preferential issuances and related approvals discussed in late 2024 and early 2025. These past actions often involved proposed changes in promoters and potential acquisitions, intended to strengthen the company's capital structure. Discussions have also occurred regarding an increase in the company's authorized share capital.

What Changes Now

• The newly issued shares will become actively traded on the BSE, increasing the total number of outstanding shares.
• The company's equity capital will grow, potentially strengthening its balance sheet.
• Stock liquidity may improve as more shares become available for trading.
• Investors will need to weigh the dilution impact against the benefits of the capital infusion.

Risks to Watch

Bijoy Hans has faced historical challenges, including poor sales growth of -10.6% over the past five years and a negative return on equity of -10.5% in recent years. Shareholders have experienced significant dilution over the past year, and the stock has historically suffered from low liquidity and average daily trading volume.

Peer Comparison

Bijoy Hans operates within the pharmaceutical and trading sectors, competing with companies such as Aptus Pharma, Hemant Surgical Industries, and Shalby Ltd. In contrast to larger peers like Redington, Bijoy Hans has a considerably smaller market capitalization.

Key Metrics

• Shareholders experienced significant dilution over the past year, with total shares outstanding increasing by 1500.7% (FY25-FY26, Standalone).
• The average daily trading volume for Bijoy Hans (BIJH) was 400 shares as of Q4 FY25.

What to Track Next

• Market reception of the newly listed shares.
• Trading volumes and price movement following the listing.
• Management's commentary on the utilization of the infused capital.
• Future financial performance indicators, particularly sales growth and profitability.
• Any further corporate actions related to ongoing promoter changes or strategic initiatives.